Vanda Pharmaceuticals: Cash Is Running Out Faster Than The Launches (NASDAQ:VNDA)
· seekingalpha.com
Vanda Pharmaceuticals Inc. stays a Sell as cash burn tops revenue, launches lag, and Phase 3 misses add risk. Click for this VNDA stock update.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions...